Do analysts prefer PYRGF or LEXX?

Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, LEXX or BGM?

Lexaria Bioscience has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexaria Bioscience $710K 12.76 -$11.90M -$5.10 N/A BGM Group $37.92M 0.77 -$19.94M N/A N/A

Is LEXX or BGM more profitable?

BGM Group's return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% BGM Group N/A N/A N/A

Do analysts rate ABVC or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ABVC or LEXX more profitable?

ABVC BioPharma's return on equity of -62.46% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% Lexaria Bioscience N/A -174.93% -143.89%

Do analysts rate TAOX or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TAOX or LEXX more profitable?

Synaptogenix's return on equity of -163.40% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Lexaria Bioscience N/A -174.93% -143.89%

Do analysts rate LEXX or OPTH?

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Lexaria Bioscience is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is LEXX or OPTH more profitable?

Optimi Health's return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% Optimi Health N/A N/A N/A

Lexaria Bioscience (LEXX) Competitors

$5.49 +0.22 (+4.17%)

As of 04:00 PM Eastern

Compare

LEXX vs. PYRGF, BGM, ABVC, TAOX, and OPTH

Should you buy Lexaria Bioscience stock or one of its competitors? Lexaria Bioscience's main competitors and related companies, chosen based on industry, sector, and market capitalization, include PyroGenesis Canada (PYRGF), BGM Group (BGM), ABVC BioPharma (ABVC), Synaptogenix (TAOX), and Optimi Health (OPTH). These companies are all part of the "pharmaceuticals" industry.

How does Lexaria Bioscience compare to PyroGenesis Canada?

PyroGenesis Canada (NASDAQ:PYRGF) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

In the previous week, PyroGenesis Canada's average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Lexaria Bioscience	Neutral

PyroGenesis Canada has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Lexaria Bioscience has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Lexaria Bioscience has a consensus target price of $22.50, suggesting a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience has lower revenue, but higher earnings than PyroGenesis Canada. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.91	-$21.12M	-$0.04	N/A
Lexaria Bioscience	$710K	12.76	-$11.90M	-$5.10	N/A

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Lexaria Bioscience beats PyroGenesis Canada on 9 of the 14 factors compared between the two stocks.

How does Lexaria Bioscience compare to BGM Group?

Lexaria Bioscience (NASDAQ:LEXX) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

13.1% of Lexaria Bioscience shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by company insiders. Comparatively, 58.7% of BGM Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Lexaria Bioscience's average media sentiment score of 0.00 equaled BGM Group'saverage media sentiment score.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
BGM Group	Neutral

Lexaria Bioscience has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

BGM Group's return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
BGM Group	N/A	N/A	N/A

Lexaria Bioscience has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	12.76	-$11.90M	-$5.10	N/A
BGM Group	$37.92M	0.77	-$19.94M	N/A	N/A

Lexaria Bioscience currently has a consensus target price of $22.50, indicating a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Lexaria Bioscience is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lexaria Bioscience beats BGM Group on 6 of the 11 factors compared between the two stocks.

How does Lexaria Bioscience compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ABVC BioPharma has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

ABVC BioPharma's return on equity of -62.46% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Lexaria Bioscience	N/A	-174.93%	-143.89%

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ABVC BioPharma has higher earnings, but lower revenue than Lexaria Bioscience. ABVC BioPharma is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	49.46	-$7.91M	-$0.40	N/A
Lexaria Bioscience	$710K	12.76	-$11.90M	-$5.10	N/A

In the previous week, ABVC BioPharma's average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Lexaria Bioscience	Neutral

Summary

ABVC BioPharma beats Lexaria Bioscience on 7 of the 13 factors compared between the two stocks.

How does Lexaria Bioscience compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Synaptogenix's return on equity of -163.40% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Lexaria Bioscience has higher revenue and earnings than Synaptogenix. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$687.84K	37.91	-$28.74M	-$13.28	N/A
Lexaria Bioscience	$710K	12.76	-$11.90M	-$5.10	N/A

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Synaptogenix has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Synaptogenix's average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Lexaria Bioscience	Neutral

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lexaria Bioscience beats Synaptogenix on 8 of the 13 factors compared between the two stocks.

How does Lexaria Bioscience compare to Optimi Health?

Lexaria Bioscience (NASDAQ:LEXX) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 309.84%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Lexaria Bioscience is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Lexaria Bioscience's average media sentiment score of 0.00 equaled Optimi Health'saverage media sentiment score.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
Optimi Health	Neutral

Optimi Health has lower revenue, but higher earnings than Lexaria Bioscience. Optimi Health is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	12.76	-$11.90M	-$5.10	N/A
Optimi Health	$290K	96.62	-$1.12M	-$0.36	N/A

Optimi Health's return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Optimi Health	N/A	N/A	N/A

13.1% of Lexaria Bioscience shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Lexaria Bioscience beats Optimi Health on 7 of the 12 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEXX vs. The Competition

Export

Metric	Lexaria Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.06M	$11.95B	$7.06B	$12.95B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-1.08	788.51	269.75	24.73
Price / Sales	12.76	967.70	652.34	108.63
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	2.75	10.33	11.27	6.42
Net Income	-$11.90M	$2.77B	$3.45B	$347.12M
7 Day Performance	15.58%	2.04%	3.56%	2.48%
1 Month Performance	-43.40%	-1.57%	-0.58%	-1.04%
1 Year Performance	-56.69%	191.33%	77.52%	23.22%

Lexaria Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
LEXX Lexaria Bioscience	2.07 of 5 stars	$5.49 +4.2%	$22.50 +309.8%	-58.4%	$9.06M	$710K	N/A	7
PYRGF PyroGenesis Canada	N/A	$0.13 -2.6%	N/A	-47.4%	$29.32M	$9.14M	N/A	90
BGM BGM Group	0.4578 of 5 stars	$0.30 +4.2%	N/A	-96.1%	$28.29M	$37.92M	N/A	298
ABVC ABVC BioPharma	0.2597 of 5 stars	$1.07 +2.9%	N/A	-62.2%	$27.62M	$510K	N/A	30
TAOX Synaptogenix	0.3151 of 5 stars	$3.76 +2.7%	N/A	-45.3%	$27.35M	$300K	N/A	4

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEXX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Competitors

LEXX vs. PYRGF, BGM, ABVC, TAOX, and OPTH

How does Lexaria Bioscience compare to PyroGenesis Canada?

Summary

How does Lexaria Bioscience compare to BGM Group?

Summary

How does Lexaria Bioscience compare to ABVC BioPharma?

Summary

How does Lexaria Bioscience compare to Synaptogenix?

Summary

How does Lexaria Bioscience compare to Optimi Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Competitors

LEXX vs. PYRGF, BGM, ABVC, TAOX, and OPTH

How does Lexaria Bioscience compare to PyroGenesis Canada?

Does the media favor PYRGF or LEXX?

Which has more volatility and risk, PYRGF or LEXX?

Is PYRGF or LEXX more profitable?

Do analysts prefer PYRGF or LEXX?

Which has preferable earnings and valuation, PYRGF or LEXX?

Do insiders and institutionals have more ownership in PYRGF or LEXX?

Summary

How does Lexaria Bioscience compare to BGM Group?

Do institutionals and insiders believe in LEXX or BGM?

Does the media prefer LEXX or BGM?

Which has more risk & volatility, LEXX or BGM?

Is LEXX or BGM more profitable?

Which has preferable valuation & earnings, LEXX or BGM?

Do analysts recommend LEXX or BGM?

Summary

How does Lexaria Bioscience compare to ABVC BioPharma?

Do analysts rate ABVC or LEXX?

Which has more volatility and risk, ABVC or LEXX?

Is ABVC or LEXX more profitable?

Do institutionals & insiders have more ownership in ABVC or LEXX?

Which has better valuation & earnings, ABVC or LEXX?

Does the media favor ABVC or LEXX?

Summary

How does Lexaria Bioscience compare to Synaptogenix?

Is TAOX or LEXX more profitable?

Which has higher valuation & earnings, TAOX or LEXX?

Do institutionals and insiders hold more shares of TAOX or LEXX?

Which has more volatility & risk, TAOX or LEXX?

Does the media favor TAOX or LEXX?

Do analysts rate TAOX or LEXX?

Summary

How does Lexaria Bioscience compare to Optimi Health?

Do analysts rate LEXX or OPTH?

Does the media refer more to LEXX or OPTH?

Which has better earnings and valuation, LEXX or OPTH?

Is LEXX or OPTH more profitable?

Do insiders and institutionals believe in LEXX or OPTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools